PATENT CLAIM ANALYSIS

Application Number: 16336363
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "234200"]

Abstract:
The present invention relates to a class of cyano-substituted-heterocycles of Formula (I) with activity as inhibitors of deubiquitilating enzymes, in particular, ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30), having utility in a variety of therapeutic areas including cancer and conditions involving mitochondrial dysfunction. (I)

Claim (Index 28):
The method according to  claim 25 , wherein the cancer is selected from breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma, bone, cancers of tissue organs, cancers of the blood cells, lymphoma, leukaemia, multiple myeloma, colorectal cancer, non-small cell lung carcinoma; cancer where apoptotic pathways are dysregulated; and cancer where proteins of the BCL-2 family are mutated, or over or under expressed.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 99.0
- Lexical Diversity: 1.32558
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['16070936', '16080506', '15738900', '15894025', '16078518']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8472994741567675
- 35 USC 102 Novelty (BERT): 0.5468633445214839
- Combined Prediction Score: 0.8172558611932392
- Mean Citation Score: 433.761262
- Max Citation Score: 448.00748
- Similarity Product: 254.4399781484604

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test